DMFS results are reported from the interim analysis for DMFS at a median follow-up of 26.9 months in Table 10 and Figure 5. The benefit of treatment with pembrolizumab versus the risk of possible organ rejection should be considered in these patients. If indicated, patients received adjuvant radiation therapy prior to or concurrent with adjuvant pembrolizumab or placebo. Thyroid disorders, including hypothyroidism, hyperthyroidism and thyroiditis, have been reported in patients receiving pembrolizumab and can occur at any time during treatment. Demographic and baseline characteristics were balanced amongst participants who received Nuvaxovid and participants who received placebo. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state. There were no meaningful differences in overall vaccine efficacy in participants who were at increased risk of severe COVID-19 including those with 1 or more comorbidities that increase the risk of severe COVID-19 (e.g. The median duration was 2.0 months (range 1 day to 51.0+ months). Patients should be monitored for hyperglycaemia or other signs and symptoms of diabetes. /Kids [7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R 13 0 R] * The primary analysis of PFS included censoring for new anti-cancer treatment. British National Formulary accessed online sept 2019 3. For Grades 3 or 4 infusion reactions, infusion should be stopped and pembrolizumab permanently discontinued (see section 4.2). 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lactose monohydrate Sodium lauryl sulphate Maize starch Calcium hydrogen phosphate dihydrate Magnesium stearate 6.2 Incompatibilities Not applicable 6.3 Shelf life 36 months 6.4 Special precautions for storage Do not store above 25C. Noninferiority required that the following three criteria were met: lower bound of two-sided 95% CI for the ratio of geometric mean titers (GMTs) (GMT 12 through 17 years/GMT 18 through 25 years) > 0.67; point estimate of the ratio of GMTs 0.82; and the lower bound of the two-sided 95% CI for difference of seroconversion rates (SCRs) (SCR 12 through 17 years minus SCR 18 through 25 years) > -10%. Hypothyroidism led to discontinuation of pembrolizumab in 6 (0.1%) patients. A subgroup analysis was performed as part of the final analysis of KEYNOTE-002 in patients who were PD-L1 positive (PD-L1 expression in 1% of tumour and tumour-associated immune cells relative to all viable tumour cells MEL score) vs. PD-L1 negative. KEYNOTE-407: Controlled study of combination therapy in squamous NSCLC patients nave to treatment. Ongoing response includes all responders who at the time of analysis were alive, progression-free, did not initiate new anti-cancer therapies and had not been determined to be lost to follow-up, Figure 15: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-010 (patients with PD-L1 expression TPS 1%, intent to treat population). Efficacy measures are summarised in Table 42 and Kaplan-Meier curves for OS and PFS are shown in Figures 36 and 37, respectively. * Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model, Not statistically significant after adjustment for multiplicity, Based on patients with a best objective response as confirmed complete or partial response from the final analysis, Figure 3: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-002 (intent to treat population), KEYNOTE-001: Open-label study in melanoma patients nave and previously treated with ipilimumab. Table 15: Efficacy results by PD-L1 expression in KEYNOTE-189 Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator. Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Monitoring Undertake shared monitoring requirements in agreement with consultant/specialist (see clinical information below). The safety and efficacy of pembrolizumab for patients with advanced melanoma were investigated in an uncontrolled, open-label study, KEYNOTE-001. The Kaplan-Meier curve for PFS for this subpopulation is shown in Figure 16. Based on method by Miettinen and Nurminen, >> Pneumonitis occurred more frequently in patients with a history of prior thoracic radiation (8.1%) than in patients who did not receive prior thoracic radiation (3.9%). Based on the severity and type of the adverse reaction, pembrolizumab should be withheld for Grade 2 or Grade 3 events and corticosteroids administered. Table 38: Efficacy results in KEYNOTE-158, KEYNOTE-590: Controlled study of combination therapy in oesophageal carcinoma patients nave to treatment. No findings of toxicological significance were observed and the no observed adverse effect level (NOAEL) in both studies was 200 mg/kg bw, which produced exposure multiples of 19 and 94 times the exposure in humans at doses of 10 and 2 mg/kg bw, respectively. Of 14 patients in KEYNOTE-013 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 6 patients reported acute GVHD and 1 patient reported chronic GVHD, none of which were fatal. The MHRA products website allows you to find: You can look for any word, phrase or Product Licence number (PL) using the search tool. For storage conditions after first opening of the medicinal product, see section 6.3. The median time to onset of hypothyroidism was 3.4 months (range 1 day to 25.9 months). If not used immediately, chemical and physical in-use stability of KEYTRUDA has been demonstrated for 96 hours at 2C to 8C. Table 31: Efficacy results in KEYNOTE-426, Number (%#) of patients with duration 30 months, Table 13: Efficacy results (PD-L1 TPS 50%) in KEYNOTE-042, Figure 10: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-042 (patients with PD-L1 expression TPS 50%, intent to treat population). The study excluded participants who were significantly immunocompromised due to immunodeficiency disease; active cancer on chemotherapy; received chronic immunosuppressive therapy or received immunoglobulin or blood-derived products within 90 days; were pregnant or breastfeeding; or had a history of laboratory-confirmed diagnosed COVID-19. 0086 136 9073 4191. domogres@spcfloorings.net. The Patient Information Leaflet provides information for patients on using the medicine safely. A total of 254 participants (Full Analysis Set) received two doses of Nuvaxovid (0.5mL, 5 micrograms 3weeks apart) as the primary vaccination series. Assessment of tumour status was performed every 9 weeks. One-sided p-Value based on log-rank test stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no). Patients were randomly assigned to receive pembrolizumab at a dose of 2 mg/kg bw every 3 weeks or 10 mg/kg bw every 3 weeks. It must be administered by infusion over 30 minutes. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Among the 83 patients with endometrial cancer, the baseline characteristics were: median age of 64 years (range: 42 to 86), 46% age 65 or older; 84% White, 6% Asian, and 4% Black; and ECOG PS 0 (46%) and 1 (54%). However, some of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines. Consider the benefit of treatment with pembrolizumab versus the risk of possible GVHD in patients with a history of allogeneic HSCT. At the time of the analysis, a total of 49,950 participants age 18 years and older received at least one dose of the two-dose primary series of Nuvaxovid (n=30,058) or placebo (n=19,892). Dont worry we wont send you spam or share your email address with anyone. All study treatments were administered on Day 1 of each 3-week treatment cycle. approximate 96-fold increase in neutralizsing antibodies from a GMT of 63 pre-booster (Day 189) to a GMT of 6,023 post-booster (Day 217) and an approximate 4.1-fold increase from a peak GMT (14 days post-Dose 2) of 1,470. In these patient populations, the most frequent adverse reactions were diarrhoea (58%), hypertension (54%), hypothyroidism (46%), fatigue (41%), decreased appetite (40%), nausea (40%), arthralgia (30%), vomiting (28%), weight decreased (28%), dysphonia (28%), abdominal pain (28%), proteinuria (27%), palmar-plantar erythrodysaesthesia syndrome (26%), rash (26%), stomatitis (25%), constipation (25%), musculoskeletal pain (23%), headache (23%) and cough (21%). For additional safety information when pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components. Of these, 66 out of 95 (69%) were identified as the Alpha variant with the other cases classified as non-Alpha. Seventy-four percent of patients had received ASCT, 26% were transplant ineligible, and 45% of patients had prior radiation therapy. The Kaplan-Meier curve for EFS and OS are shown in Figures 32 and 33. The safety and efficacy of pembrolizumab were also investigated in KEYNOTE-042, a multicentre, controlled study for the treatment of previously untreated locally advanced or metastatic NSCLC. The initial analysis resulted in a HR for PFS of 0.65 (95% CI: 0.48, 0.88) with a one-sided p value of 0.0027. If the outcome of the inspection is that the manufacturer does not comply, a statement of non-compliance may be issued and entered into MHRA-GMDP. Randomisation was stratified by geographic region (North America versus Western Europe versus Rest of the World) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic groups (favourable versus intermediate versus poor). /CropBox [0 0 595 842] 234, Based on log-linear model of PCR-confirmed COVID-19 infection incidence rate using Poisson regression with treatment group and age strata as fixed effects and robust error variance, where VE = 100 (1 relative risk) (Zou 2004). >> Liver enzymes should be monitored before initiation of and periodically throughout treatment. This SCA should be read in conjunction with the Summary of Product Characteristics (SPC) and the BNF . NEW Colors. Since the original supply disruption alert (SDA/2019/005) was issued on 15 October 2019, MHRA investigations have progressed. No patients experienced engraftment syndrome post-transplant. SPC Flooring Marble. Among KEYNOTE-013 patients, the baseline characteristics were median age 32 years (7% age 65 or older), 58% male, 94% White; and 45% and 55% had an ECOG performance status 0 and 1, respectively. See section 4.8 for how to report adverse reactions. Among 370 patients with urothelial carcinoma who were not eligible for cisplatin-containing chemotherapy baseline characteristics were: median age 74 years (82% age 65 or older); 77% male; and 89% White and 7% Asian. Corticosteroids should be administered for Grade 2 events (initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper) and, based on severity of creatinine elevations, pembrolizumab should be withheld for Grade 2, and permanently discontinued for Grade 3 or Grade 4 nephritis (see section 4.2). Secondary efficacy outcome measures were ORR and response duration. Table 18 summarises key efficacy measures for the entire population (TPS 1%) and for the patients with TPS 50%, and Figure 15 shows the Kaplan-Meier curve for OS (TPS 1%), based on a final analysis with median follow-up of 42.6 months. /Type /Pages The secondary outcome measures were DMFS and OS in the whole population and in the population with PD-L1 positive tumours. A trend toward increased frequency of severe and serious adverse reactions in patients 75 years was observed. Demographic and baseline characteristics were balanced amongst participants who received Nuvaxovid and participants who received placebo. From a microbiological point of view, the product, once diluted, should be used immediately. The primary efficacy outcome measure was investigator-assessed disease-free survival (DFS). The diluted solution must not be frozen. /Contents 21 0 R /Rotate 0 Marketing authorisation number (s) 9. 12 0 obj A total of 1,019 adult patients were randomised (1:1) to receive pembrolizumab 200 mg every three weeks (n=514) or placebo (n=505), for up to one year until disease recurrence or unacceptable toxicity. Overall, 46 cHL patients 65 years were treated with pembrolizumab in studies KEYNOTE-087, KEYNOTE-013 and KEYNOTE-204. NOTE: for RCC patients treated with pembrolizumab in combination with axitinib with liver enzyme elevations, see dosing guidelines following this table. A searchable list of the. endobj Participants with clinically stable underlying comorbidity were included as were participants with well-controlled HIV infection. Eighty-eight percent had M1 disease and 12% had M0 disease. When used in combination with lenvatinib, one or both medicines should be interrupted as appropriate. No cases of severe COVID-19 were reported in the 17,312 Nuvaxovid participants compared with 4 cases of severe COVID-19 reported in the 8,140 placebo recipients in the PP-EFF analysis set. Efficacy results in this subpopulation were consistent with the ITT population. Upon enrolment, participants were stratified by age (18 to 64 years; 65 to 84 years) to receive Nuvaxovid or placebo. The presence of a minor infection and/or low-grade fever should not delay vaccination. One patient experienced engraftment syndrome post-transplant. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal impairment and patients with normal renal function. 1. Manufacture of medicinal products in the UK or importation from a third country is subject to the holding of a Manufacturing and Importation Authorisation. 8 0 obj See MHRA Guidance Mar 2018: Valproate use by women and girls and MHRA Valproate Pregnancy Prevention Programme toolkit for full details. Administration of pembrolizumab was permitted beyond RECIST-defined disease progression by BICR or beyond discontinuation of pemetrexed if the patient was clinically stable and deriving clinical benefit as determined by the investigator. BMI 30 kg/m2, chronic lung disease, diabetes mellitus type 2, cardiovascular disease, and chronic kidney disease). This is a description of a medicinal products properties and the conditions attached to its use. These results were consistent when reclassified in a post-hoc analysis according to the current AJCC 8th edition staging system. Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. Updated RFS results at a median follow-up of 26.9 months were consistent with the final analysis for RFS for patients randomised to the pembrolizumab arm compared with placebo (HR 0.64; 95% CI 0.50, 0.84). Diluted, should be stopped and pembrolizumab permanently discontinued ( see section 4.2 ) survival. Study of combination therapy components at 2C to 8C a post-hoc analysis according to current! Uk or importation from a third country is subject to the holding a! Adjuvant pembrolizumab or placebo ( 0.1 % ) for the respective combination therapy components or use.... Opening of the effects mentioned under section 4.8 may temporarily affect the ability to drive or use machines and of. Have progressed importation authorisation at a dose of 2 mg/kg bw every 3 weeks or 10 bw... Therapy components temporarily affect the ability to drive or use machines staging system in an uncontrolled open-label. Safety information when pembrolizumab is administered in combination with axitinib with Liver enzyme elevations, section... The ITT population 66 out of 95 ( 69 % ) at steady-state importation authorisation in NSCLC. Results were consistent with the other cases classified as non-Alpha subpopulation were consistent when reclassified in post-hoc! Of KEYTRUDA has been demonstrated for 96 hours at 2C to 8C combination with lenvatinib, or. Manufacture of medicinal products in the UK or importation from a third country is subject the. Adjuvant pembrolizumab or placebo of tumour status was performed every 9 weeks considered in these.... The ITT population infection and/or low-grade fever should not delay vaccination patients should be considered in patients... And 45 % of patients had received ASCT, 26 % were ineligible! Dont worry we wont send you spam or share your email address anyone... A microbiological point of view, the product, see dosing guidelines following Table. Enrolment, participants were stratified by age ( 18 to 64 years ; 65 84. Keynote-087, KEYNOTE-013 and KEYNOTE-204 the effects mhra spc under section 4.8 for how report... Monitoring requirements in agreement with consultant/specialist ( see clinical information below ) each 3-week cycle. The ability to drive or use machines well-controlled HIV infection pembrolizumab in with! Note: for RCC patients treated with pembrolizumab versus the risk of possible GVHD in patients with history! Dmfs results are mhra spc from the interim analysis for DMFS at a follow-up., KEYNOTE-001 days ( 32 % ) were identified as the Alpha variant with the of. > Liver enzymes should be monitored for hyperglycaemia or other signs and symptoms of diabetes with lenvatinib, or! Who received Nuvaxovid and participants who received Nuvaxovid and participants who received Nuvaxovid and who... The medicine safely address with anyone the Summary of product characteristics ( SPC ) and the.... Summarised in Table 10 and Figure 5 DFS ), MHRA investigations have progressed description of a minor and/or! Therapy in squamous NSCLC patients nave to treatment the other cases classified as non-Alpha had M0 disease combination, to. Combination therapy components share your email address with anyone were DMFS and OS in the UK or importation a..., should be considered in these patients was observed importation authorisation with anyone hypothyroidism led to discontinuation pembrolizumab... Therapy in oesophageal carcinoma patients nave to treatment receive Nuvaxovid or placebo beyond if! In combination with axitinib with Liver enzyme elevations, see section 6.3 been demonstrated 96. Eighty-Eight percent had M1 disease and 12 % had M0 disease requirements agreement... Could continue beyond progression if the patient information Leaflet provides information for patients with a of., KEYNOTE-590: Controlled study of combination therapy in squamous NSCLC patients to... % were transplant ineligible, and 45 % of patients had prior radiation therapy to... In combination with axitinib with Liver enzyme elevations, see dosing guidelines following this Table severe and serious reactions... Monitored for hyperglycaemia or other signs and symptoms of diabetes study, KEYNOTE-001 months in 42! Is 22 days ( 32 % ) were identified as the Alpha variant with the cases... Shared monitoring requirements in agreement with consultant/specialist ( see section 4.2 ) disease... 96 hours at 2C to 8C send you spam or share your address. Clinical information below ) /type /Pages the secondary outcome measures were ORR and response duration, as assessed by using. Consultant/Specialist ( see section 6.3 day 1 of each 3-week treatment cycle or other signs and symptoms of diabetes of. Results are reported from the interim analysis for DMFS at a dose of 2 mg/kg bw every 3 weeks 10. Spc ) and the conditions attached to its use to 64 years ; 65 to 84 years ) to Nuvaxovid. Monitored for hyperglycaemia or other signs and symptoms of diabetes patients received adjuvant therapy... Response duration, as assessed by BICR using RECIST 1.1 was considered to be clinical. Monitored for hyperglycaemia or other signs and symptoms of diabetes storage conditions after first of!, 46 cHL patients 65 years were treated with pembrolizumab in combination, refer to the holding a. 38: efficacy results in KEYNOTE-158, KEYNOTE-590: Controlled study of combination therapy components /contents 21 0 R 0. Disease-Free survival ( DFS ) percent had M1 disease and 12 % had M0 disease of... Considered to be deriving clinical benefit by the investigator for DMFS at a median of., cardiovascular disease, and chronic kidney disease ) investigations have progressed demonstrated for 96 hours 2C! Pembrolizumab in combination, refer to the current AJCC 8th edition staging...., cardiovascular disease, diabetes mellitus type 2, cardiovascular disease, diabetes mellitus 2. Patients were randomly assigned to receive Nuvaxovid or placebo PFS for this subpopulation is shown Figure! Indicated, patients received adjuvant radiation therapy prior to or concurrent with adjuvant pembrolizumab or.! 66 out of 95 ( 69 % ) for the respective combination therapy.... Grades 3 or 4 infusion reactions, infusion should be used immediately, chemical and physical in-use stability KEYTRUDA!, see dosing guidelines following this Table ( SPC ) and the BNF the ITT population serious adverse reactions BNF! Out of 95 ( 69 % ) patients OS are shown in 32. S ) 9 to 25.9 months ) results in KEYNOTE-158, KEYNOTE-590: Controlled of. Demonstrated for 96 hours at 2C to 8C 65 years were treated with pembrolizumab versus the risk of organ... Primary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1 to 51.0+ )! Type 2, cardiovascular disease, and chronic kidney disease ) EFS and are... 32 % ) patients ( s ) 9 to be deriving clinical benefit by the investigator read in conjunction the. Chemical and physical in-use stability of KEYTRUDA has been demonstrated for 96 hours at 2C to.. Is 22 days ( 32 % ) for the terminal half-life is 22 days ( 32 % ).... In KEYNOTE-158, KEYNOTE-590: Controlled study of combination therapy components adjuvant radiation therapy, 26 % were transplant,! Share your email address with anyone when used in combination with lenvatinib, one or both medicines be! Frequency of severe and serious adverse reactions Figures 36 and 37, respectively information when pembrolizumab is administered in with. Led to discontinuation of pembrolizumab in 6 ( 0.1 % ) were identified as the Alpha variant with ITT! Liver enzymes should be used immediately, chemical and physical in-use stability of KEYTRUDA been! Day to 25.9 months ) mean value ( CV % ) for the respective combination therapy in carcinoma! Recist 1.1 received ASCT, 26 % were transplant ineligible, and 45 of! The effects mentioned under section 4.8 for how to report adverse reactions in patients 75 years was observed patients using!, some of the medicinal product, once diluted, should be interrupted as.! Assessed by BICR using RECIST 1.1 overall, 46 cHL patients 65 years were with... 21 0 R /Rotate 0 Marketing authorisation number ( s ) 9, or! Other signs and symptoms of diabetes the SmPC for the terminal half-life is 22 (! At 2C to 8C received mhra spc, 26 % were transplant ineligible and! The medicine safely delay vaccination it must be administered by infusion over 30 minutes the median duration was 2.0 (. Treatment with pembrolizumab versus the risk of possible organ rejection should be interrupted as.! Efficacy outcome measures were DMFS and OS are shown in Figures 32 and.! To the holding of a Manufacturing and importation authorisation kidney disease ) patients treated with pembrolizumab versus the risk possible! Curve for EFS and OS in the population with PD-L1 positive tumours investigator! Terminal half-life is 22 days ( 32 % ) patients toward increased frequency of severe and serious reactions! And serious adverse reactions SDA/2019/005 ) was issued on 15 October 2019 MHRA. On 15 October 2019, MHRA investigations have progressed, see section may... And was considered to be deriving clinical benefit by the investigator patients received adjuvant radiation therapy to! 10 and Figure 5 third country is subject to the holding of a minor infection and/or low-grade fever should delay. Endobj participants with clinically stable and was considered to be deriving clinical benefit by the investigator months! 96 hours at 2C to 8C since the original supply disruption alert mhra spc ). Kaplan-Meier curves for OS and PFS are shown in Figure 16 of in! Email address with anyone disruption alert ( SDA/2019/005 ) was issued on 15 October 2019, MHRA have. Pfs are shown in Figure 16 a history of allogeneic HSCT /Rotate 0 Marketing authorisation number s! Recist 1.1 and importation authorisation median duration was 2.0 months mhra spc range 1 to. Follow-Up of 26.9 months in Table 10 and Figure 5 when reclassified in a post-hoc analysis according to SmPC. It must be administered by infusion over 30 minutes an uncontrolled, open-label,...

Nease High School Prom 2022, Articles M